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Abstract: Hippocampal pathology occurs early in Alzheimer disease
(AD), and atrophy, measured by volumes and volume changes, may
predict which subjects will develop AD. Measures of the temporal
horn (TH), which is situated adjacent to the hippocampus, may also
indicate early changes in AD. Previous studies suggest that these
metrics can predict conversion from amnestic mild cognitive impair-
ment (MCI) to AD with conversion and volume change measured
concurrently. However, the ability of these metrics to predict future
conversion has not been investigated. We compared the abilities of
hippocampal, TH, and global measures to predict future conversion
from MCI to AD. TH, hippocampi, whole brain, and ventricles were
measured using baseline and 12-month scans. Boundary shift integral
was used to measure the rate of change. We investigated the prediction
of conversion between 12 and 24 months in subjects classiﬁed as MCI
from baseline to 12 months. All measures were predictive of future
conversion. Local and global rates of change were similarly predictive
of conversion. There was evidence that the TH expansion rate is more
predictive than the hippocampal atrophy rate (P=0.023) and that the
TH expansion rate is more predictive than the TH volume (P=0.036).
Prodromal atrophy rates may be useful predictors of future conversion
to sporadic AD from amnestic MCI.
Key Words: hippocampus, Alzheimer disease, atrophy, longitudinal
studies, magnetic resonance imaging
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Dementia is estimated to aﬀect >80 million peopleworldwide by 2040.1 The most common cause of
dementia is Alzheimer disease (AD).2 Conﬁrmation of AD
requires histopathologic examination of brain tissue, usually
at postmortem. Brain atrophy can be measured at autopsy,
with cortical volumes reported to be lower than controls,3
and atrophy can be seen in vivo using magnetic resonance
imaging (MRI). An early site of AD tau pathology is the
hippocampus4 and this is mirrored by increased hippocampal
atrophy.5,6 Because of the physical proximity of the temporal
horn (TH) to the hippocampus, changes in TH structure may
reﬂect those of the hippocampus. Indeed, the volumes of
these 2 structures have been shown to correlate,7 and AD
subjects have signiﬁcantly greater hippocampal and TH rates
of change than controls.8 After medial temporal tissue loss,
generalized cortical atrophy occurs with corresponding in-
creases in whole-brain volume losses.9,10
Identifying subjects who are likely to develop AD
would allow potential disease-modifying treatments to be
given before patients become severely impaired. Subjects
with amnestic mild cognitive impairment (MCI) who have
measurable memory deﬁcits have an increased risk of
converting to AD of around 12% per year compared with
1% to 2% for controls.11 However, not all MCI subjects
convert to AD and therefore predicting converters would be
useful for the clinician and for the patient and their carers.
Hippocampal volume is predictive of conversion from
MCI to AD.5,12–16 However, cross-sectional volumes may
have large intersubject variances that are unrelated to the
disease, and not all studies have found diﬀerences in the hip-
pocampal volume between converters and nonconverters.17
Using the atrophy rate may reduce intersubject variance and
provide a better prediction of future converters.
Studies suggest that the hippocampal atrophy rate can
predict AD conversion.15,18,19 However, these studies
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calculated the atrophy rate within the time frame of con-
version and thus assess only the concurrent conversion.
Few studies have assessed TH expansion rates and AD
conversion, but 1 study reported that TH expansion rates of
presymptomatic subjects [before second clinical dementia
rating (CDR)=0.5] are higher in converters than in stable
MCI.13 It is therefore interesting to investigate the power of
TH expansion rates to predict the prospective conversion
of amnestic MCI subjects to AD, which may be useful in
the recruitment of patients in clinical trials that target
prodromal AD subjects.
Global measures such as whole brain and ventricles
have reportedly higher rates of volume change in subjects
who convert from MCI to AD than in nonconverters.20,21
The brain parenchymal fraction (percentage of intracranial
cavity occupied by brain tissue)22 and the brain and ven-
tricular rate of change16 have been shown to predict the
conversion from MCI to AD. However, 1 study found no
diﬀerence in the baseline brain volume or atrophy rate
between converters and nonconverters23 and another
showed that neither the whole-brain volume nor the atro-
phy rate was predictive of conversion from MCI to AD.15
Our aims were (1) to investigate whether hippocampal
and TH rates of change can predict which amnestic MCI
subjects will convert to AD in the future; (2) to assess
whether local regions (hippocampi and THs) have a higher
predictive value than less disease-speciﬁc global measures
(whole brain and ventricles); and (3) to examine whether
using rates of change yields a higher predictive value than
cross-sectional volumes.
METHODS
Subjects
Subjects were a subset of the Alzheimer’s Disease
Neuroimaging Initiative (ADNI) cohort. ADNI is a mul-
ticentre public/private-funded longitudinal study inves-
tigating adult subjects with AD, amnestic MCI, and normal
cognition. Participants underwent baseline and periodic
clinical and neuropsychometric assessments and serial
MRI. Details are available at http://www.adni-info.org.
Written informed consent was obtained, as approved by the
Institutional Review Board, at each of the participating
centers. ADNI inclusion and exclusion criteria are detailed
elsewhere (http://adni.loni.ucla.edu/wp-content/uploads/
2010/09/ADNI_GeneralProceduresManual.pdf).
Subjects included in the current study were classiﬁed as
MCI at the time of their baseline visit and remained as MCI
up to and including their 12-month visit. Subjects in the
ADNI study were classiﬁed as MCI according to the Pe-
tersen criteria.11 MCI subjects had an Mini Mental State
Examination score of 24 to 30, a CDR of 0.5, and were
amnestic. Subjects were included in the current study if they
had 1.5T scans available at the baseline and 12 months
(n=335), which were downloaded from the LONI website
(http://www.loni.ucla.edu/ADNI). Patient diagnosis was
recorded at 6-month intervals for 24 months. Seventy
subjects were excluded because they did not have a stable
diagnosis from baseline to 12 months. A further 39 subjects
were excluded because of poor-quality scans (on the basis
of the internal quality control). Subjects were classiﬁed as
converters if they converted to AD between 12 months and
24 months and as stable if they did not convert by 24
months. Criteria for the diagnosis of AD were based on the
National Institute of Neurological and Communicative
Disorders and Stroke and the Alzheimer’s Disease and
Related Disorders Association criteria for probable AD.
Subjects with AD had an MMSE of 20 to 26 and a CDR of
0.5 or 1. Subjects who converted but then withdrew from
the study were not excluded from the analysis (n=6), but
stable subjects were included only if they were conﬁrmed
stable at or after 24 months. Twenty-eight subjects were
excluded because they could not be conﬁrmed as stable at
24 months. Of the remaining subjects, 1 was diagnosed with
semantic dementia (but also classiﬁed as MCI from baseline
to 24months) and 1 had a diagnosis of shy dragger syn-
drome (and was classiﬁed as MCI until 24months when
they also had a diagnosis of AD) during the study period.
These 2 subjects were not excluded from the study as they
still had classiﬁcations of MCI or AD throughout the study
period.
MRI Acquisition
Details can be found elsewhere (http://adni.loni.ucla.
edu/wp-content/uploads/2008/11/mritrainingmanual-adn_
a4b28.pdf).24 T1-weighted volumetric scans were acquired
using 1.5 T Siemens Medical Solutions, Philips Medical
Systems, or General Electric Healthcare units. Represen-
tative imaging parameters were repetition time=2400ms,
inversion time=1000ms, echo time=3.5ms, ﬂip an-
gle=8 degrees, ﬁeld of view=240240mm and 160
sagittal 1.2-mm–thick slices and a 192192 matrix yield-
ing a voxel resolution of 1.251.251.2mm3, or 180
sagittal 1.2-mm–thick slices with a 256256 matrix
yielding a voxel resolution of 0.940.941.2mm3. Im-
ages were corrected for distortion due to gradient non-
linearity,25 image intensity nonuniformity (using N326 for
all images and B127 where required), and scaling-corrected
on the basis of phantom measures.24
Region Creation
Hippocampal and TH regions were created on baseline
and 12-month scans after registration to a standard tem-
plate using 6 degrees of freedom.28 Hippocampal regions
were generated using hippocampal multiatlas propaga-
tion and segmentation as described by Leung et al.29 In
brief, a template library was used to ﬁnd the best-matched
atlases for each individual hippocampus in the target image.
The hippocampi in the top 8 atlases were nonlinearly reg-
istered and propagated to the target image. The 8 hippo-
campal segmentations were combined to produce a single
consensus segmentation using the simultaneous truth and
performance level estimation algorithm.30
TH, whole-brain, and ventricle regions were created
using the MIDAS software.31 For THs, a threshold of 60%
mean brain intensity deﬁned the brain-cerebrospinal ﬂuid
(CSF) boundary, with manual editing where required. The
posterior boundary of the TH was the slice before which the
atrium of the lateral ventricle joins the TH. THs were
segmented by a single segmentor blinded to diagnosis and
laterality. The TH segmentation time was around 5 minutes
per scan. Intraclass correlation for the within-rater reli-
ability for TH volume was >0.99 for an independent group
of 10 AD and 10 control subjects. Whole-brain and ven-
tricular segmentation is detailed elsewhere.31,32 Twelve-
month whole-brain regions were generated by propagating
baseline regions to the 12-month scans after nonrigid reg-
istration.33 The within-rater and between-rater reliability
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intraclass correlation for 11 segmentors was >0.99 for 5
independent scans for brain and ventricle volumes.
The intracranial volume (TIV) was used as a measure
of head size.29 TIV was calculated from the summation of
gray matter, white matter, and CSF volumes. Individual
volumes were calculated by summing (over voxels) the
values of probabilistic tissue segmentations produced using
SPM8 (http://www.ﬁl.ion.ucl.ac.uk/spm/software/spm8)
multiplied by the voxel volume.
Measuring Rates of Change
Rates of change were measured using the boundary shift
integral (BSI),34,35 which estimates volume change by sum-
ming intensity shifts of serial registered images in the boun-
dary area of serial registered regions. Hippocampal BSI was
calculated from registered baseline and 12-month scans using
the baseline hippocampal regions and a double-intensity
window approach29 to capture changes across the CSF—
hippocampal and the white matter—hippocampal borders.
TH BSI was calculated using the baseline TH region and a
single-intensity window to capture changes across the TH—
brain border. Whole-brain and ventricle BSI were calculated
using linearly registered baseline and 12-month scans using
the whole-brain and ventricular regions.
Statistical Analyses
Analyses were performed using Stata version 10. Dif-
ferences between stable subjects and converters for baseline
characteristics of age, scan interval, and MMSE score were
assessed using a 2-sample t test. Diﬀerences between stable
subjects and converters for sex and APOE E4 carriers were
assessed using Fisher exact test.
Annualized hippocampal and whole-brain atrophy rates
were calculated as a percentage of baseline change per year
using a back-transformed arithmetic scale; TH and ventricular
rates of expansion were calculated as milliliter change per year
using an arithmetic scale. Cross-sectional hippocampal and
TH volumes were measured on the 12-month scans in ac-
cordance with the literature,5,12–16 which examines diagnostic
changes occurring immediately after volume measurement.
Diﬀerences in group means for cross-sectional volumes and
rates of change were assessed using a 2-sample t test.
To quantify the predictive value of each measure, we
estimated the area under the receiver operating character-
istic curve (AUC)36 and tested the null hypothesis that this
equaled 0.5 using the Wilcoxon rank-sum test. An AUC
value of 0.5 corresponds to no predictive value, whereas an
AUC of 1 represents perfect discrimination between groups
(converters and stable). The AUC is the probability that for
a randomly chosen converter/stable pair, the converter has a
higher (or more abnormal) value for the given measure than
the stable subject. We calculated 95% conﬁdence intervals
for the AUCs and compared AUCs between measures using
the Stata command roccomp, which uses the nonparametric
method proposed by DeLong et al.37 Logistic regression was
used to assess whether TIV adjustment improved the pre-
diction above that aﬀorded by each measure by ﬁtting the
model with TIV and the measure as explanatory variables.
RESULTS
Subjects
The ﬁnal cohort consisted of 137 stable and 61 con-
verter subjects. Baseline characteristics for age, scan inter-
val, sex, APOE E4 status, and MMSE are shown in Table 1.
Volumes and Rates
Group Statistics and Predictive Values
Table 2 shows baseline and 12-month volumes and
rates of change for the hippocampus, TH, whole brain, and
ventricle, and P-values (testing the null hypothesis of no
diﬀerence between converters and stable). Table 3 shows
AUCs, 95% conﬁdence intervals, and P-values (testing the
null hypothesis of no predictive value) for all measures.
There was statistically signiﬁcant evidence that each meas-
ure had some predictive value, with the estimated AUCs
indicating a moderately strong predictive power.
Hippocampal and TH Rates of Change
Comparing the AUCs, there was evidence that the TH
expansion rate had a greater predictive value than the
hippocampal atrophy rate (P=0.023).
Local and Global Rates of Change
There was no evidence that the hippocampal atrophy
rate (P=0.24) or the TH rate of change (P=0.21) im-
proved the prediction of conversion compared with the
whole-brain atrophy rate. Similarly, there was no evidence
that the predictive value of ventricular rates diﬀered from
that of the hippocampal (P=0.19) or the TH (P=0.19)
rate of change.
Rates of Change and Cross-Sectional Volume
A logistic regression model incorporating the hippo-
campus volume and the TIV ﬁt the data no better than the
hippocampus volume alone (P=0.09). TIV was, therefore,
not used in subsequent hippocampal analyses. Comparing
AUCs, there was no signiﬁcant diﬀerence between the
hippocampal volume and the hippocampal atrophy rate
(P=0.90).
A logistic regression model incorporating the TH vol-
ume and TIV did not ﬁt the data any better than the TH
volume alone (P=0.75), and so TIV was not used in further
TH statistical models. There was some evidence that the
AUC of the TH rate of change was higher than that of the
TH volume (P=0.036).
DISCUSSION
We found evidence that the TH and the hippocampal
rate of change were predictive of prospective conversion from
MCI to AD in the following year. There was some evidence
TABLE 1. Baseline Characteristics for Stable Subjects and
Converters
Stable Converters
n 137 61 P
Age 75.1 (6.7)
[57.9, 88.0]
74.4 (7.5)
[56.3, 87.8]
0.51
Scan interval (y) 1.08 (0.07)
[0.96, 1.34]
1.08 (0.08)
[0.97, 1.34]
0.79
Male 88 (64.2) 39 (63.9) 0.55
APOE E4 carriers 63 (46.0) 45 (73.8) <0.001
MMSE 27.39 (1.65)
[24, 30]
26.54 (1.62)
[24, 30]
<0.001
Mean (SD) [minimum, maximum], except sex and APOE E4 carriers,
which show the number (percentage).
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that the TH expansion rate had a greater predictive value
than the hippocampal atrophy rate. Global rates of change
(whole brain and ventricles) were predictive of future cogni-
tive decline. However, there was no evidence of diﬀerences in
the predictive ability of local and global rates of change.
Comparing the predictive ability of atrophy rates and vol-
umes suggested that the TH rate of change was a better
predictor than the TH volume. The analogous comparison
with hippocampi showed no evidence of a diﬀerence. To the
authors’ knowledge, this is the ﬁrst paper to assess future
conversion to AD in stable MCI patients using atrophy rate
measurements of the hippocampus and TH.
Changes in brain and ventricular volume were predictive
of future decline to AD, but we found no evidence that their
predictive value was less than that of the volume changes in the
hippocampus.4 The absence of a predictive advantage for re-
gions aﬀected early in the disease such as the hippocampi may
be because larger losses outside the temporal lobe are neces-
sary before clinical conversion to AD. This explanation is also
consistent with our ﬁnding that THs have a greater predictive
ability than hippocampi as the TH are likely to reﬂect wider
changes throughout the temporal lobe, and not just the
hippocampus. Other studies have demonstrated atrophy
spreading from the medial temporal lobe to other brain
areas.9,10 The current study used relatively impaired MCI
subjects38 who may be further along the disease process and
may be past the point where atrophy is localized. To establish
whether more localized changes occur earlier in the disease,
early MCI subjects should be investigated, such as those being
recruited in ADNI GO and ADNI 2 (http://adni.loni.ucla.edu/
about/about-the-study/). It may be the case that changes in
hippocampal atrophy rates that occur before conversion are
smaller, relative to between-subject diﬀerences in rates, than
for TH expansion rates. Alternatively, hippocampal atrophy
rates may be measured with greater measurement error, which
would lead to reduced predictive power.
Our ﬁnding that the TH expansion rate is a signiﬁcant
predictor of future conversion from MCI to AD is con-
sistent with Erten-Lyons et al,13 who found that the pre-
symptomatic TH expansion rate was associated with stable
and decliner MCI group membership. Similarly, our ﬁnding
that the hippocampal atrophy rate was predictive of future
decline is consistent with Henneman et al15 and Wang
et al.18 However, these studies included subjects who con-
verted to AD before their second scan, whereas our study
included only subjects who converted after the second scan,
thus assessing future, rather than concurrent, conversion.
Our ﬁnding that global rates of change were predictive
of conversion is inconsistent with Henneman et al,15 but
consistent with Jack et al.16 Diﬀerences between the studies’
designs may explain this inconsistency. Henneman et al.
used a lower strength scanner (1.0 T, compared with 1.5T
for Jack et al. and the present study), which may have
contributed to a greater measurement error. Furthermore,
Henneman et al. had fewer subjects (44 MCI, compared
with 72 in Jack et al. and 198 in the present study), and
consequently less power to detect an eﬀect. We found little
previous work on comparing the predictive ability of local
and global measurements, although Jack et al16 found that
the cross-sectional hippocampal volume yielded comple-
mentary predictive information to whole-brain and ven-
tricular rates of change. Although we found no diﬀerence
in the predictive value of local and global measurements,
TABLE 2. Mean (SD) Baseline and 12-month Raw Volumes and Rates of Change for Stable Subjects and
Converters
Stable Converters
n 137 61 P
Baseline volumes (mL)
Hippocampus 4.61 (0.85) 4.31 (0.93) 0.030
TH 1.41 (1.18) 1.87 (1.40) 0.030
Whole brain 1065.7 (110.0) 1051.7 (132.2) 0.47
Ventricle 43.6 (23.2) 47.9 (24.3) 0.25
12month volumes (mL)
Hippocampus 4.46 (0.86) 4.08 (0.93) 0.0080
TH 1.59 (1.32) 2.22 (1.65) 0.0096
Whole brain 1055.0 (111.1) 1034.2 (128.3) 0.27
Ventricle 46.2 (24.4) 51.9 (25.4) 0.14
Rates of change
Hippocampus (% baseline volume/y) 2.34 (2.22) 3.24 (2.49) 0.017
TH (mL/y) 0.144 (0.161) 0.282 (0.247) <0.001
Brain (% baseline volume/y) 0.84 (0.75) 1.26 (0.64) <0.001
Ventricle (mL/y) 2.11 (2.08) 3.63 (2.27) <0.001
P-values test the null hypothesis of no diﬀerence in the means between converters and stable subjects.
TH indicates temporal horn.
TABLE 3. AUC Representing the Value of the 12-month Rate
of Change and Baseline Volumes in Predicting Subsequent
Conversion, 95% Confidence Intervals, and P-values Testing the
Null Hypothesis That the AUC Equals 0.5 for Each of the Measures
95% Conﬁdence
Interval
AUC Lower Upper P
Hippocampal atrophy rate 0.624 0.536 0.712 0.005
TH expansion rate 0.728 0.654 0.80 <0.001
Brain atrophy rate 0.679 0.600 0.758 <0.001
Ventricle expansion rate 0.687 0.609 0.766 <0.001
Hippocampus volume 0.617 0.532 0.703 0.008
TH volume 0.655 0.576 0.733 <0.001
AUC indicates area under the receiver operator curve; TH, temporal
horn.
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we only assessed these using rates of change, whereas
Jack et al. used the volume for the local (hippocampal)
measurement.
Our ﬁnding that the hippocampal volume was predictive
of future decline is consistent with several studies.5,12–16 Our
ﬁnding that the TH baseline volume was also predictive is in-
consistent with Erten-Lyons et al,13 who found no diﬀerence
between stable and declinerMCI groups. This discrepancy may
arise from diﬀerences in group deﬁnitions; all subjects in Erten-
Lyons et al. started as normal controls—stable MCI were
subjects who were MCI by the end of the study, but did not
progress to AD—whereas our stable subjects started with a
diagnosis of MCI. Our subjects were also younger (stable mean
75.1y, converters 74.4 compared with 85.7 and 87.7 for stable
and decliners, respectively in Erten-Lyons et al.).
Our hippocampal atrophy rates were generally con-
sistent with the literature. Our mean stable hippocampal
atrophy rates (2.3%/y) were comparable to those reported
previously, which ranged from 2.3% to 2.5% per year,39,40
and our median hippocampal atrophy rates (2.1%/y) were
reasonably similar to that of Jack et al,20 who reported a
median of 1.8% per year. Jack et al39 and Archer et al40
report mean hippocampal atrophy rates for declining MCI
subjects of 3.7% and 3.6% per year, respectively; the
analogous value from our converters was 3.2% per year.
Likewise, Jack et al20 reported a median value for hippo-
campal converters as 3.3% per year, which is comparable to
3.1% per year for our converters. Note that our converter
group diﬀers from these studies because we include only
subjects converting after 1 year, whereas the other studies
include any subjects converting from baseline.
We found only 1 study that reported TH expansion
rates in MCI subjects. Erten-Lyons et al13 reported a 3% per
year TH expansion rate (estimated from a graph) for MCI
stable subjects. Analogous rates for stable subjects in our
study are 10.8% per year. As Erten-Lyons et al. stable MCI
subjects started the study as controls and changed to an MCI
status, the annualized rates of change may be expected to be
lower than our study. Interestingly, the TH expansion rate of
declining MCI subjects in the Erten-Lyons et al. paper is 17%
per year, which is more comparable to the rates of our con-
verters (17.4% per year).
A limitation of this study is that only a subset of the
ADNI data set was used, mostly because we included good-
quality scans only. Our results pertain to the prediction of
imminent (in the next year) conversion. It is important to
note that although the stable subjects have not yet converted
to AD, they may still convert in the future. Further, we note
that the ﬁndings of this study may be relevant only to am-
nestic MCI because subjects with other forms of MCI
(nonamnestic MCI and multidomainMCI) were not included
in the ADNI study. However, studies suggest that amnestic
MCI subjects may represent a transitional zone from normal
aging to AD41,42; it is therefore appropriate to focus on
amnestic MCI in the current study to assess future conversion
to AD. Finally, some subjects were excluded because their
conversion status was unavailable. This may bias our results
if these excluded subjects diﬀer with respect to the value of
the imaging measures in predicting conversion. Strengths of
the study include its multisite nature, careful diagnosis at 6-
month intervals, and examination of future diagnosis change
in MCI subjects, which is more clinically relevant and useful
than concurrent diagnosis change.
This study demonstrates that TH, hippocampus,
whole-brain, and ventricular rates of change and TH and
hippocampal volumes are predictive of future decline to
AD from MCI using serial MRI. We found no evidence
that regions susceptible to early change were more pre-
dictive of future decline than global measures. However,
there was some evidence that the TH expansion rate had a
greater predictive ability than the hippocampi atrophy rate.
There was also some evidence that the TH expansion rate
was a better predictor than the TH cross-sectional volume.
In conclusion, prodromal atrophy rates may be useful
predictors of future conversion to sporadic AD from MCI.
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